Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone

Mitochondrial toxins such as the complex 1 inhibitor rotenone are widely used as pesticides and may be present in military environments. Administration of rotenone can induce biochemical and histological alterations similar to those of Parkinson's disease in rats. However, only a subset of animals show these effects and it is unclear whether more subtle alterations are caused by chronic administration of rotenone in those animals that appear resistant to its toxic effects on dopaminergic nerve terminals. To address this question, vehicle or rotenone (2.0, 2.5, or 3.5 mg/kg/day) was administered intravenously or subcutaneously for 21 days to adult rats, and rotenone effects on survival, motor behavior, and striatal tyrosine hydroxylase immunoreactivity (TH-IR) were examined. Both intravenous and subcutaneous rotenone induced a dose-dependent decrease in survival rates. Surviving animals showed a decrease in spontaneous rearing. Locomotor activity and movement initiation time were also altered in some of the experimental groups. Confirming previous results, TH-IR in the striatum was markedly decreased in rats that fell ill early in the study and in a few of the surviving rats with high rotenone doses. However, none of the surviving rats receiving 2.0 mg/kg/day showed TH-IR loss reminiscent of Parkinson's disease, and loss of striatal TH-IR across doses was not correlated with motor behavior in individual rats. Thus, chronic administration of low doses of rotenone induces motor anomalies even in animals that do not develop histological signs of Parkinson's disease, indicating a pervasive neurological effect of moderate mitochondrial dysfunction in vivo.

[1]  H. Checkoway,et al.  Epidemiologic approaches to the study of Parkinson's disease etiology. , 1999, Epidemiology.

[2]  J. Langston,et al.  Environmental Risk Factors and Parkinson's Disease: Selective Degeneration of Nigral Dopaminergic Neurons Caused by the Herbicide Paraquat , 2002, Neurobiology of Disease.

[3]  M. Zigmond,et al.  Neurochemical compensation after nigrostriatal bundle injury in an animal model of preclinical parkinsonism. , 1984, Archives of neurology.

[4]  G Fiskum,et al.  Mitochondria in Neurodegeneration: Acute Ischemia and Chronic Neurodegenerative Diseases , 1999, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[5]  Jean Féger,et al.  Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats , 2003, Journal of neurochemistry.

[6]  M. Horne,et al.  Axonal sprouting following lesions of the rat substantia nigra , 2000, Neuroscience.

[7]  S. Haber,et al.  Striatal Responses to Partial Dopaminergic Lesion: Evidence for Compensatory Sprouting , 2000, The Journal of Neuroscience.

[8]  B. Liu,et al.  Synergistic Dopaminergic Neurotoxicity of the Pesticide Rotenone and Inflammogen Lipopolysaccharide: Relevance to the Etiology of Parkinson's Disease , 2003, The Journal of Neuroscience.

[9]  M. Beal,et al.  Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[10]  A. Björklund,et al.  Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[11]  Joseph P Huston,et al.  Behavioral phenotyping of the MPTP mouse model of Parkinson's disease , 2001, Behavioural Brain Research.

[12]  J. Nobrega,et al.  Brain Cytochrome Oxidase in Alzheimer's Disease , 1992, Journal of neurochemistry.

[13]  Robert Hill,et al.  Low platelet mitochondrial complex I and complex II/III activity in early untreated parkinson's disease , 1995, Annals of neurology.

[14]  I. Silver,et al.  Methylmalonate toxicity in primary neuronal cultures , 1998, Neuroscience.

[15]  James R. Burke,et al.  Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines , 2002, Nature Neuroscience.

[16]  D. Higgins,et al.  In Vivo Labeling of Mitochondrial Complex I (NADH:UbiquinoneOxidoreductase) in Rat Brain Using [3H]Dihydrorotenone , 2000, Journal of neurochemistry.

[17]  J. Schulz,et al.  Systemic administration of rotenone produces selective damage in the striatum and globus pallidus, but not in the substantia nigra , 1997, Brain Research.

[18]  C. C. Johnson,et al.  The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living , 1998, Neurology.

[19]  S. Wachtel,et al.  Biochemical and anatomical characterization of forepaw adjusting steps in rat models of Parkinson's disease: studies on medial forebrain bundle and striatal lesions , 1999, Neuroscience.

[20]  T. Schallert,et al.  CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury , 2000, Neuropharmacology.

[21]  J. Parks,et al.  Abnormalities of the electron transport chain in idiopathic parkinson's disease , 1989, Annals of neurology.

[22]  R. Duvoisin,et al.  Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. , 1984, Science.

[23]  B. Ritz,et al.  Parkinson's disease mortality and pesticide exposure in California 1984-1994. , 2000, International journal of epidemiology.

[24]  E. Love,et al.  Parkinson's disease and exposure to agricultural work and pesticide chemicals , 1992, Neurology.

[25]  Todd B. Sherer,et al.  Subcutaneous Rotenone Exposure Causes Highly Selective Dopaminergic Degeneration and α-Synuclein Aggregation , 2003, Experimental Neurology.

[26]  C. Hertzman,et al.  A case‐control study of Parkinson's disease in a horticultural region of British Columbia , 1994, Movement disorders : official journal of the Movement Disorder Society.

[27]  T. Robinson,et al.  Compensatory changes in striatal dopamine neurons following recovery from injury induced by 6-OHDA or methamphetamine: a review of evidence from microdialysis studies. , 1990, Canadian journal of psychology.

[28]  T. Robinson,et al.  Changes in striatal dopamine neurotransmission assessed with microdialysis following recovery from a bilateral 6-OHDA lesion: variation as a function of lesion size , 1990, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[29]  J. M. Ree,et al.  Behavioural changes after different stress paradigms: prepulse inhibition increased after physical, but not emotional stress , 2003, European Neuropsychopharmacology.

[30]  R. Gross,et al.  3-Nitropropionic acid exacerbates N-methyl-d-aspartate toxicity in striatal culture by multiple mechanisms , 1998, Neuroscience.

[31]  M. Chesselet,et al.  Toxicity of Dopamine to Striatal Neurons In Vitro and Potentiation of Cell Death by a Mitochondrial Inhibitor , 1998, Journal of neurochemistry.

[32]  Todd B. Sherer,et al.  Selective microglial activation in the rat rotenone model of Parkinson's disease , 2003, Neuroscience Letters.

[33]  Todd B. Sherer,et al.  Chronic systemic pesticide exposure reproduces features of Parkinson's disease , 2000, Nature Neuroscience.

[34]  M. Beal,et al.  Mitochondria in Neurodegeneration: Bioenergetic Function in Cell Life and Death , 1999, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[35]  B. Liu,et al.  Distinct Role for Microglia in Rotenone-Induced Degeneration of Dopaminergic Neurons , 2002, The Journal of Neuroscience.

[36]  R. Schwarting,et al.  Evidence for a Dissociation between MPTP Toxicity and Tyrosinase Activity Based on Congenic Mouse Strain Susceptibility , 2001, Experimental Neurology.

[37]  W. Schmidt,et al.  Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats , 2002, Behavioural Brain Research.

[38]  T. Montine,et al.  Manganese ethylene‐bis‐dithiocarbamate and selective dopaminergic neurodegeneration in rat: a link through mitochondrial dysfunction , 2003, Journal of neurochemistry.

[39]  R. Gainetdinov,et al.  Glutamatergic modulation of hyperactivity in mice lacking the dopamine transporter , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[40]  Y. Kagawa,et al.  Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. , 1989, Biochemical and biophysical research communications.

[41]  G. Kreutzberg Microglia: a sensor for pathological events in the CNS , 1996, Trends in Neurosciences.

[42]  M. Zigmond,et al.  Forced Limb-Use Effects on the Behavioral and Neurochemical Effects of 6-Hydroxydopamine , 2001, The Journal of Neuroscience.

[43]  Bin Liu,et al.  Role of Microglia in Inflammation-Mediated Neurodegenerative Diseases: Mechanisms and Strategies for Therapeutic Intervention , 2003, Journal of Pharmacology and Experimental Therapeutics.

[44]  Bertrand Bloch,et al.  Differential regulation of tyrosine hydroxylase in the basal ganglia of mice lacking the dopamine transporter , 1999, The European journal of neuroscience.

[45]  Shelley R. Winn,et al.  Implantation of encapsulated catecholamine and GDNF-producing cells in rats with unilateral dopamine depletions and parkinsonian symptoms , 1995, Experimental Neurology.

[46]  D. Jacobowitz,et al.  A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[47]  T. Schallert,et al.  A Clinically Relevant Unilateral Rat Model of Parkinsonian Akinesia , 1992, Journal of Neural Transplantation & Plasticity.

[48]  S. Rapoport,et al.  Impairment in mitochondrial cytochrome oxidase gene expression in Alzheimer disease. , 1994, Brain research. Molecular brain research.

[49]  B. Hyman,et al.  Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[50]  M. Zigmond,et al.  Forced Nonuse in Unilateral Parkinsonian Rats Exacerbates Injury , 2002, The Journal of Neuroscience.

[51]  P. Teitelbaum,et al.  Excessive bracing reactions and their control by atropine and l-DOPA in an animal analog of parkinsonism , 1979, Experimental Neurology.

[52]  A. H. V. Schapira,et al.  MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSON'S DISEASE , 1989, The Lancet.

[53]  R. Wightman,et al.  Profound neuronal plasticity in response to inactivation of the dopamine transporter. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[54]  P. Sanberg,et al.  Central Nervous System Diseases , 2000, Contemporary Neuroscience.